Results 11 to 20 of about 1,182,968 (316)

Parkinson’s Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway

Cells, 2021
Parkinson’s disease (PD) is one of the major neurodegenerative diseases (ND) which presents a progressive neurodegeneration characterized by loss of dopamine in the substantia nigra pars compacta.
Alexandre Vallée, Jean-Noël Vallée, Yves Lecarpentier   +2 more
doaj   +2 more sources

Lithium: a potential therapeutic strategy in obsessive–compulsive disorder by targeting the canonical WNT/β pathway

Translational Psychiatry, 2021
Obsessive–compulsive disorder (OCD) is a neuropsychiatric disorder characterized b–y recurrent and distinctive obsessions and/or compulsions. The etiologies remain unclear.
Alexandre Vallée, Jean-Noël Vallée, Yves Lecarpentier   +2 more
doaj   +2 more sources

Lithium Toxicity in the Setting of Nonsteroidal Anti-Inflammatory Medications [PDF]

Case Reports in Nephrology, 2013
Lithium toxicity is known to affect multiple organ systems, including the central nervous system. Lithium levels have been used in the diagnosis of toxicity and in assessing response to management. There is evidence that nonsteroidal anti-inflammatory medications (NSAIDs) can increase lithium levels and decrease renal lithium clearance.
Syed Adeel Hassan, Fatimah Khalid, Zaid Alirhayim, Syed Amer   +3 more
openalex   +4 more sources

Lithium-induced nephrogenic diabetes insipidus following improved medication compliance: a case report

Journal of Medical Case Reports
Background Nephrogenic diabetes insipidus is a rare, often underrecognized complication of long-term lithium therapy. Lithium-induced nephrogenic diabetes insipidus results from chronic renal exposure, leading to significant polyuria, dehydration, and ...
Eugene Annor, Ishita Bhattacharya, Mary Bass, Emily M. Horvath   +3 more
doaj   +2 more sources

Differential acute impact of therapeutically effective and overdose concentrations of lithium on human neuronal single cell and network function

Translational Psychiatry, 2021
Lithium salts are used as mood-balancing medication prescribed to patients suffering from neuropsychiatric disorders, such as bipolar disorder and major depressive disorder.
Julia Izsak, Henrik Seth, Margarita Iljin, Stephan Theiss, Hans Ågren, Keiko Funa, Ludwig Aigner, Eric Hanse, Sebastian Illes   +8 more
doaj   +2 more sources

Lithium: new observations on an old medication [PDF]

Neuroscience Letters, 2022
Mirko Manchia, Alessio Squassina
openalex   +3 more sources

Transcription-Driven Repurposing of Cardiotonic Steroids for Lithium Treatment of Severe Depression [PDF]

Cells
Lithium is prescribed as a mood stabilizer for bipolar disorder and severe depression. However, the mechanism of action of lithium is unknown and there are major side effects associated with prolonged medication.
Richard Killick, Claudie Hooper, Cathy Fernandes, Christina Elliott, Dag Aarsland, Svein R. Kjosavik, Ragnhild Østerhus, Gareth Williams   +7 more
doaj   +2 more sources

Short-term and long-term effects of Muslim fasting on lithium pharmacokinetics and renal function in bipolar disorder: a prospective observational study [PDF]

International Journal of Bipolar Disorders
This prospective observational study aimed to investigate the effects of Ramadan fasting on serum lithium levels, renal function, and electrolyte balance in patients with bipolar disorder undergoing lithium maintenance therapy. Conducted in Saudi Arabia,
Mohamed Abouzed, Abdullah Saleh Altuhayni, Salwa Rashed Alshammari, Mohamed Saad Almuqahhwi, Mohamed Elgernas, Abdulkarim Almazyadi, Abdullah Abdulaziz Alghuraymil, Yousef Ibrahim, Awwad Alenezy   +8 more
doaj   +2 more sources

Lithium, an Infrequently Used Medication [PDF]

The Canadian Journal of Psychiatry, 2019
Scott B. Patten, Jeanne V.A. Williams
openalex   +4 more sources

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial

Health Technology Assessment
Background Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly, and none for longer than 8 weeks.
Jess Kerr-Gaffney, Zohra Zenasni, Kimberley Goldsmith, Nahel Yaziji, Huajie Jin, Alessandro Colasanti, John Geddes, David Kessler, R Hamish McAllister-Williams, Allan H Young, Alvaro Barrera, Lindsey Marwood, Rachael W Taylor, Helena Tee, Anthony J Cleare   +14 more
doaj   +2 more sources